Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 12/2018

01-11-2018 | Breast Oncology

Reply to "Questions About In-Breast Tumor Recurrence in Patients Treated with Breast-Conserving Therapy"

Authors: James Laird, BA, Lior Z. Braunstein, MD

Published in: Annals of Surgical Oncology | Issue 12/2018

Login to get access

Excerpt

Dr. Altundag raises an interesting question regarding the influence of breast cancer biologic subtype on survival after a local recurrence.1 Although we previously reported that subtype approximations do maintain prognostic significance after a first recurrence,2 in the context of the current study, this raises another issue about the propensity for a breast cancer recurrence to harbor ductal carcinoma in situ (DCIS) as a function of the primary disease subtype. This was addressed in Table 2, demonstrating no significant differences in the rates between true recurrence (TR) and new primaries (NP) by biologic subtype. …
Literature
1.
2.
Braunstein LZ et al (2015) Outcome following local-regional recurrence in women with early-stage breast cancer: impact of biologic subtype. Breast J. 21(2):161–167CrossRef
Metadata
Title
Reply to "Questions About In-Breast Tumor Recurrence in Patients Treated with Breast-Conserving Therapy"
Authors
James Laird, BA
Lior Z. Braunstein, MD
Publication date
01-11-2018
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 12/2018
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-017-6286-4

Other articles of this Issue 12/2018

Annals of Surgical Oncology 12/2018 Go to the issue

Thoracic Oncology

Beyond TNM: Searching for New Patient-Centric Prognostic Indicators in NSCLC

Gynecologic Oncology

BRCA Mutation Status to Personalize Management of Recurrent Ovarian Cancer: A Multicenter Study

Health Services Research and Global Oncology

Race and Health Disparities in Patient Refusal of Surgery for Early-Stage Pancreatic Cancer: An NCDB Cohort Study

Thoracic Oncology

Recurrence Risk Based on Pathologic Stage After Neoadjuvant Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Implications for Risk-Based Postoperative Surveillance Strategies

ASO Author Reflections

Abilities of Pre- and Postoperative High-Sensitivity C-Reactive Protein Levels to Predict 90-Day Mortality After Surgery for Abdominal and Thoracic Cancers

Breast Oncology

Utility of Expedited Hereditary Cancer Testing in the Surgical Management of Patients with a New Breast Cancer Diagnosis